D. Western Therapeutics Institute, Inc. (4576.T)
JPY 118.0
(3.51%)
JPY 118.0
(3.51%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.14 Billion JPY | 63.85% |
| 2022 | 726.44 Million JPY | 28.35% |
| 2021 | 565.97 Million JPY | -6.33% |
| 2020 | 604.24 Million JPY | 53.69% |
| 2019 | 393.16 Million JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 414.48 Million JPY | -7.14% |
| 2024 Q2 | 227.93 Million JPY | -45.01% |
| 2023 Q4 | 446.35 Million JPY | 42.82% |
| 2023 Q3 | 312.53 Million JPY | 26.22% |
| 2023 Q2 | 247.61 Million JPY | 34.75% |
| 2023 Q1 | 183.75 Million JPY | 6.36% |
| 2023 FY | 1.19 Billion JPY | 63.85% |
| 2022 FY | 726.44 Million JPY | 28.35% |
| 2022 Q3 | 200.77 Million JPY | 0.0% |
| 2022 Q4 | 172.77 Million JPY | -13.95% |
| 2021 FY | 565.97 Million JPY | -6.33% |
| 2020 FY | 604.24 Million JPY | 53.69% |
| 2019 FY | 393.16 Million JPY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 1.28 Billion JPY | 11.128% |
| PRISM BioLab Co.,LTD | 576.81 Million JPY | -97.903% |
| GNI Group Ltd. | 9.32 Billion JPY | 87.755% |
| Linical Co., Ltd. | 2.7 Billion JPY | 57.802% |
| Trans Genic Inc. | 2.15 Billion JPY | 47.147% |
| MEDINET Co., Ltd. | 1.49 Billion JPY | 23.446% |
| Soiken Holdings Inc. | 3.07 Billion JPY | 62.829% |
| Cytori Cell Research Institute, Inc. | 1.85 Billion JPY | 38.527% |
| AnGes, Inc. | 8.9 Billion JPY | 87.177% |
| OncoTherapy Science, Inc. | 943.08 Million JPY | -21.043% |
| Nxera Pharma Co., Ltd. | 19.19 Billion JPY | 94.051% |
| Immuno-Biological Laboratories Co., Ltd. | 412.99 Million JPY | -176.407% |
| NanoCarrier Co., Ltd. | 975.37 Million JPY | -17.036% |
| Carna Biosciences, Inc. | 2.56 Billion JPY | 55.54% |
| CanBas Co., Ltd. | 278 Million JPY | -310.624% |
| RaQualia Pharma Inc. | 1.81 Billion JPY | 37.208% |
| Chiome Bioscience Inc. | 1.6 Billion JPY | 28.821% |
| Kidswell Bio Corporation | 2.37 Billion JPY | 51.916% |
| PeptiDream Inc. | 9.68 Billion JPY | 88.216% |
| Oncolys BioPharma Inc. | 1.96 Billion JPY | 41.776% |
| Ribomic Inc. | 1.1 Billion JPY | -3.242% |
| SanBio Company Limited | 4.53 Billion JPY | 74.851% |
| Healios K.K. | 3.48 Billion JPY | 67.263% |
| BrightPath Biotherapeutics Co., Ltd. | 1.15 Billion JPY | 1.143% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 1.33 Billion JPY | 14.457% |
| Delta-Fly Pharma, Inc. | 1.4 Billion JPY | 18.663% |
| StemRIM | 2.07 Billion JPY | 45.013% |
| CellSource Co., Ltd. | 1.96 Billion JPY | 41.862% |
| FunPep Company Limited | 313.82 Million JPY | -263.754% |
| Kringle Pharma, Inc. | 958.01 Million JPY | -19.157% |
| Stella Pharma Corporation | 963.98 Million JPY | -18.418% |
| TMS Co., Ltd. | 943.25 Million JPY | -21.021% |
| Noile-Immune Biotech Inc. | 1.08 Billion JPY | -4.733% |
| Cuorips Inc. | 598.11 Million JPY | -90.854% |
| K Pharma,Inc. | 543.94 Million JPY | -109.863% |
| Takara Bio Inc. | 23.9 Billion JPY | 95.225% |
| ReproCELL Incorporated | 1.51 Billion JPY | 24.602% |
| PhoenixBio Co., Ltd. | 1.18 Billion JPY | 3.586% |
| StemCell Institute Inc. | 1.16 Billion JPY | 1.772% |
| Japan Tissue Engineering Co., Ltd. | 1.52 Billion JPY | 25.011% |
| CellSeed Inc. | 804.93 Million JPY | -41.818% |